These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21670925)

  • 1. Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil.
    Vidal JE; Freitas AC; Song AT; Campos SV; Dalben M; Hernandez AV
    Braz J Infect Dis; 2011; 15(3):245-8. PubMed ID: 21670925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.
    Poveda E; de Mendoza C; Martin-Carbonero L; Corral A; Briz V; González-Lahoz J; Soriano V
    J Antimicrob Chemother; 2007 Oct; 60(4):885-8. PubMed ID: 17646201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
    Lambert-Niclot S; Flandre P; Canestri A; Peytavin G; Blanc C; Agher R; Soulié C; Wirden M; Katlama C; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2008 Feb; 52(2):491-6. PubMed ID: 18039922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.
    Delaugerre C; Pavie J; Palmer P; Ghosn J; Blanche S; Roudiere L; Dominguez S; Mortier E; Molina JM; de Truchis P
    AIDS; 2008 Sep; 22(14):1809-13. PubMed ID: 18690163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.
    Bethell R; Scherer J; Witvrouw M; Paquet A; Coakley E; Hall D
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):1019-24. PubMed ID: 22098079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance profile of darunavir: combined 24-week results from the POWER trials.
    de Meyer S; Vangeneugden T; van Baelen B; de Paepe E; van Marck H; Picchio G; Lefebvre E; de Béthune MP
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):379-88. PubMed ID: 18327986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virologic and immunologic effectiveness at 48 weeks of darunavir-ritonavir-based regimens in treatment-experienced persons living with HIV-1 infection in clinical practice: a multicenter Brazilian cohort.
    Biscione FM; Westin MR; Ribeiro KM; Estevam DL; Cardoso SW; Tenore SB; Neto LF; Alencastro PR; Suffert TA; de Moraes MJ; Barbosa AN; Morejón KM; de Arruda ÉA; Silveira JM; Neto JL; Greco DB; Tupinambás U
    J Int Assoc Provid AIDS Care; 2014; 13(1):63-8. PubMed ID: 24134962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.
    Donegan KL; Walker AS; Dunn D; Judd A; Pillay D; Menson E; Lyall H; Tudor-Williams G; Gibb DM; ;
    Antivir Ther; 2012; 17(4):599-603. PubMed ID: 22300840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.
    Poveda E; de Mendoza C; Parkin N; Choe S; García-Gasco P; Corral A; Soriano V
    AIDS; 2008 Mar; 22(5):611-6. PubMed ID: 18317002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
    De Luca A; Di Giambenedetto S; Maserati R; Gianotti N; Narciso P; Antinori A; Di Perri G; Prosperi MC; Baldanti F; Micheli V; Zazzi M; Perno CF; Santoro MM; ;
    Antivir Ther; 2011; 16(4):489-97. PubMed ID: 21685536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
    AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.
    Sterrantino G; Zaccarelli M; Colao G; Baldanti F; Di Giambenedetto S; Carli T; Maggiolo F; Zazzi M;
    Infection; 2012 Jun; 40(3):311-8. PubMed ID: 22237471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment.
    Rolle CP; Marquez O; Nguyen V; Hinestrosa F; DeJesus E
    Int J STD AIDS; 2020 Sep; 31(10):958-966. PubMed ID: 32698728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
    Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
    HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
    Delaugerre C; Mathez D; Peytavin G; Berthé H; Long K; Galperine T; de Truchis P
    AIDS; 2007 May; 21(9):1210-3. PubMed ID: 17502734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major drug resistance mutations to HIV-1 protease inhibitors (PI) among patients exposed to PI class failing antiretroviral therapy in São Paulo State, Brazil.
    Soldi GFR; Ribeiro IC; Ahagon CM; Coelho LPO; Cabral GB; Lopes GISL; Ferreira JLP; Brígido LFM;
    PLoS One; 2019; 14(10):e0223210. PubMed ID: 31574109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).
    Delaugerre C; Buyck JF; Peytavin G; Viard JP; Chaix ML; Zucman D; Mortier E; Blanche S; Rouveix E; Force G; Aegerter P; de Truchis P
    J Clin Virol; 2010 Mar; 47(3):248-52. PubMed ID: 20097121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients.
    Spagnuolo V; Gianotti N; Seminari E; Galli L; Fusetti G; Salpietro S; Lazzarin A; Castagna A
    J Acquir Immune Defic Syndr; 2009 Feb; 50(2):192-5. PubMed ID: 19131889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.